Andrew HunzekerHesed traded consumer-scale applications for pioneering AI-native technology in the life sciences by becoming the founding engineer at 10x Science, a startup dedicated to transforming proteomics and drug discovery through innovative scientific analysis software.
- Andrew transitioned from high-profile tech roles to foundational AI science software
- 10x Science pioneers AI-native tools targeting drug discovery and proteomics
- Startup culture enabled rapid innovation and direct impact on life sciences
What happened
Andrew HunzekerHesed, previously a Principal Engineer at Grindr with experience on large-scale consumer software projects, joined 10x Science as its first employee. He was drawn by the company’s approach to AI—grounded in first principles and scientific inquiry rather than commercialized AI models. After a multi-day trial working closely with 10x Science’s founders, Andrew accepted the challenge to help build AI-powered scientific analysis tools.
Within his first week, Andrew contributed directly to crafting a solution for a top-ten pharmaceutical company’s challenge, an urgent project that became integral to 10x Science’s portfolio. This rapid involvement exemplified the startup’s all-hands-on-deck ethos and marked a significant shift from the typical engineering roles Andrew had known.
Why it matters
10x Science is developing AI-native software tailored to scientific data processes such as proteomics and drug discovery, fields demanding precise and innovative computational tools. Andrew’s move highlights how top engineering talent is increasingly drawn to early-stage ventures that prioritize fundamental problem-solving over simply scaling existing technologies.
By immersing in early product discovery, Andrew is helping bridge software engineering with scientific research, contributing to efforts that could accelerate breakthroughs within life sciences. Unlike roles in large companies focused on scaling, his work involves conceptualizing and creating the core technology that drives future growth and customer impact.
What to watch next
As 10x Science transitions from exploratory research to developing product features for paying customers, the coming months will reveal how the startup’s AI-native approach performs in commercial life sciences applications. Close attention should be paid to how their tools are adopted in proteomics and drug discovery workflows and whether they can fundamentally improve efficiency or insights in these areas.
Andrew’s experience suggests the company values nimble, principled engineering coupled with a deep understanding of scientific domains. For investors and life sciences operators, 10x Science could be a key player to monitor for innovations at the intersection of AI and complex biological data analysis.